# Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

> **NCT00300365** · PHASE2 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 38 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** Pioglitazone
- **OTHER:** Placebo
- **DRUG:** Niacin ER
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT00300365
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300365, "Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00300365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*